Rabia Gurses Ozden, M.D.

Chief Medical Officer

Rabia Gurses Ozden, MD brings over 15 years of experience in clinical development, clinical operations, and pharmacovigilance in pharmaceutical and medical device development with proven capabilities in global program and project management as well as experience interacting with the FDA, EMA, PMDA, and CFDA for regulatory filings, new clinical endpoint development, and label negotiations. Prior to joining Ocular, Rabia served as the Chief Development Officer at Akouos, Inc. Previous to her role at Akouos, she served as Chief Medical Officer of Nightstar a gene therapy company focused on rare inherited retinal diseases, which was acquired by Biogen. She has held leadership positions at Applied Genetic Technologies Corporation and GlaxoSmithKline, and earlier in her career held clinical development and operations roles at Quark Pharmaceuticals, Baush & Lomb Pharmaceuticals and Carl Zeiss Meditec. Rabia received her M.D. from Hacettepe University School of Medicine, completed her ophthalmology residency at Ankara University School of Medicine, and her clinical fellowship in Glaucoma at the New York Eye and Ear Infirmary.